How many 8-K filings has Akebia Therapeutics, Inc. filed?

Akebia Therapeutics, Inc. (AKBA) has 28 8-K (Current Event Report) filings on record, spanning Jan 2024 to May 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Akebia Therapeutics, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Akebia Therapeutics, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Akebia Therapeutics, Inc. (AKBA) — 8-K Filings

All 8-K filings from Akebia Therapeutics, Inc.. Browse 28 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (28)

8-K Filing — May 7, 2026
8-K Filing — Apr 1, 2026
Akebia Therapeutics Files 8-K: Material Agreement, FD Disclosure — Dec 1, 2025 Risk: medium
On November 28, 2025, Akebia Therapeutics, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and reported othe
8-K Filing — Nov 17, 2025
Akebia Therapeutics Files 8-K — Oct 28, 2025 Risk: low
Akebia Therapeutics, Inc. filed an 8-K on October 28, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, o
Akebia Therapeutics Files 8-K on Financials — Aug 7, 2025 Risk: low
On August 7, 2025, Akebia Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as
Akebia Therapeutics Reports Director/Officer Changes & Shareholder Votes — Jun 13, 2025 Risk: medium
Akebia Therapeutics, Inc. filed an 8-K on June 13, 2025, reporting events as of June 10, 2025. The filing indicates changes related to the departure of director
Akebia Therapeutics Files 8-K — May 8, 2025 Risk: low
Akebia Therapeutics, Inc. filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhib
Akebia Therapeutics Files 8-K: Material Agreement, Other Events — Mar 20, 2025 Risk: medium
On March 19, 2025, Akebia Therapeutics, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and reported other e
Akebia Therapeutics Files 8-K on Financials — Mar 13, 2025 Risk: low
Akebia Therapeutics, Inc. filed an 8-K on March 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statemen
Akebia Therapeutics Enters Material Agreement, Reports Equity Sales — Feb 7, 2025 Risk: medium
On February 3, 2025, Akebia Therapeutics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported u
Akebia Therapeutics Files 8-K — Jan 13, 2025 Risk: low
On January 13, 2025, Akebia Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and
Akebia Therapeutics Files 8-K — Nov 7, 2024 Risk: low
Akebia Therapeutics, Inc. filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition, as well as financial statements and
Akebia Therapeutics Files 8-K Report — Oct 22, 2024 Risk: low
On October 22, 2024, Akebia Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update
Akebia Therapeutics Signs Material Definitive Agreement — Oct 16, 2024 Risk: medium
On October 15, 2024, Akebia Therapeutics, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, i
Akebia Therapeutics Files 8-K on Financials — Aug 8, 2024 Risk: low
Akebia Therapeutics, Inc. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition. The filing includes financial statemen
Akebia Therapeutics Terminates Vifor Pharma Agreement — Jul 11, 2024 Risk: medium
On July 10, 2024, Akebia Therapeutics, Inc. announced the termination of its Material Definitive Agreement with Vifor Pharma Group. This termination is related
Akebia Therapeutics Elects New Directors — Jun 24, 2024 Risk: low
On June 21, 2024, Akebia Therapeutics, Inc. announced changes to its Board of Directors. Specifically, the company elected two new directors, Dr. Marc Dunoyer a
Akebia Therapeutics Holds Stockholder Meeting — Jun 10, 2024 Risk: low
Akebia Therapeutics, Inc. filed an 8-K on June 10, 2024, reporting that on June 6, 2024, the company held a special meeting of its stockholders. The primary pur
Akebia Therapeutics Files 8-K on Financials — May 9, 2024 Risk: low
Akebia Therapeutics, Inc. filed an 8-K on May 9, 2024, to report on its results of operations and financial condition, as well as to file financial statements a
Akebia Therapeutics Secures $50M Loan — Apr 23, 2024 Risk: medium
On April 17, 2024, Akebia Therapeutics, Inc. entered into a loan and security agreement with Kreos Capital VIII (UK) Limited, drawing down $50 million under a t
Akebia Therapeutics Enters Material Definitive Agreement — Apr 16, 2024 Risk: medium
On April 15, 2024, Akebia Therapeutics, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, its
Akebia Therapeutics Completes $200M Senior Secured Notes Offering — Mar 28, 2024 Risk: medium
On March 27, 2024, Akebia Therapeutics, Inc. announced the successful completion of its previously disclosed offering of 10.0% senior secured notes due 2029. Th
Akebia Therapeutics Announces Board Changes and Executive Compensation — Mar 15, 2024 Risk: medium
On March 15, 2024, Akebia Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the filin
Akebia Therapeutics Files 8-K — Mar 14, 2024 Risk: low
Akebia Therapeutics, Inc. filed an 8-K on March 14, 2024, reporting on its results of operations and financial condition, as well as filing financial statements
Akebia Therapeutics Files 8-K on Officer/Director Changes — Feb 13, 2024 Risk: medium
The 8-K filing by Akebia Therapeutics, Inc. (CIK: 0001517022) on February 13, 2024, reports an event on February 8, 2024, related to the departure or election o
Akebia Therapeutics Reports New Debt, Equity Sales, and Agreement Changes — Jan 30, 2024
Akebia Therapeutics, Inc. filed an 8-K on January 30, 2024, reporting events from January 29, 2024, including the entry into and termination of a material defin
Akebia Therapeutics Files Routine 8-K on Operations & Financial Condition — Jan 8, 2024
Akebia Therapeutics, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition, as well as to make a Regulation FD di

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX